Date Posted, by Sharon Reynolds
On May 14, the Food and Drug Administration (FDA) expanded the approvals of two tests that detect cancer-causing types of human papillomavirus (HPV) in the cervix. Both tests are used as part of screening for cervical cancer.
In this NCI Cancer Currents Blog DCP's Dr. Vikrant Sahasrabuddhe explains how the FDA's recent expanded approvals of self-collection devices for HPV screening relates to the recently launched SHIP (Self-collection for HPV testing to Improve Cervical Cancer Prevention) Trial.
Read the blog: https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-hpv-te…